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blood cells exposed to alpha particle radiation
Vinita Chauhan*, Matthew Howland and Ruth WilkinsAbstract
Background: The threat of a terrorist-precipitated nuclear event places humans at danger for radiological exposures.
Isotopes which emit alpha (α)-particle radiation pose the highest risk. Currently, gene expression signatures are being
developed for radiation biodosimetry and triage with respect to ionizing photon radiation. This study was designed
to determine if similar gene expression profiles are obtained after exposures involving α-particles.
Methods: Peripheral blood mononuclear cells (PBMCs) were used to identify sensitive and robust gene-based
biomarkers of α-particle radiation exposure. Cells were isolated from healthy individuals and were irradiated at
doses ranging from 0-1.5 Gy. Microarray technology was employed to identify transcripts that were differentially
expressed relative to unirradiated cells 24 hours post-exposure. Statistical analysis identified modulated genes at
each of the individual doses.
Results: Twenty-nine genes were common to all doses with expression levels ranging from 2-10 fold relative to
control treatment group. This subset of genes was further assessed in independent complete white blood cell
(WBC) populations exposed to either α-particles or X-rays using quantitative real-time PCR. This 29 gene panel
was responsive in the α-particle exposed WBCs and was shown to exhibit differential fold-changes compared to
X-irradiated cells, though no α-particle specific transcripts were identified.
Conclusion: Current gene panels for photon radiation may also be applicable for use in α-particle radiation
biodosimetry.
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Nuclear terrorism is a global concern with illicit traffic-
king events involving nuclear material on the rise [1].
Between 1993 and 2011, the International Atomic
Energy Association (IAEA) documented 2164 nuclear
material incidents or malicious acts and 588 involved
the theft or loss of nuclear or radioactive materials. A
further 18 of these involved plutonium or highly
enriched uranium. Such events highlight the potential
for radioactive material to fall into the wrong hands and
potentially being used for the fabrication of a radio-
logical dispersal device (RDD) [2]. Los Alamos National
Laboratory has conducted a thorough review of RDD
source material and has postulated that four of the nine
isotopes most likely to be employed are α-particle* Correspondence: Vinita.chauhan@hc-sc.gc.ca
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unless otherwise stated.emitters, primarily due to their minimal shielding
requirements and ease of concealment [3]. There is also
the concern of long-term contamination due to these
isotopes’ long half-lives and the severe biological damage
that can occur from a minimal dose of exposure.
In recent years, much work has gone towards develo-
ping strategies for radiation biodosimetry with a specific
focus on photon radiation [4-8]. However, the strategies
currently employed for photon radiation may not pro-
vide adequate dose estimates for α-particle exposures.
Unlike photon radiation, α-particles travel a short
distance (40-70 μm) and create very dense ionizing
tracks as they traverse a medium. They typically cause an
energy deposition of 160 keV•μm-1 for 2.5 MeV α-particles
in comparison to 2.0 keV•μm-1 for low linear energy trans-
fer (LET) X-rays [9,10]. Therefore, α-particles produce
more significant biological effects when compared to equal
absorbed doses from low-LET photon radiation, whichal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Chauhan et al. BMC Medical Genomics 2014, 7:43 Page 2 of 16
http://www.biomedcentral.com/1755-8794/7/43are more sparsely ionizing [11-13]. This difference in
ionization density may provide a means of distinguishing
radiation type based on the magnitude of the biological
response.
Development of biomarker-based biodosimetry has
been put forth as one of the key priority development
areas for nuclear threat countermeasures [14], and micro-
array data/gene based profiling has served as timely and
minimally invasive means to address this priority area [15].
There have been several studies examining the gene ex-
pression profiles of human cells using functional genomics
platforms for photon radiation [16-18]. However, the avai-
lability of similar gene tools for high LET radiation types,
such as α-particles, remains limited. To date, the majority
of α-particle transcriptional studies have been performed
in vitro using transformed or normal cell types [19-21].
There has also been a selected few studies that have
profiled genomic changes and compared the responses
following exposure of cells to different radiation types
[22,23]. Microarray studies in our own lab using epidermal
keratinocytes exposed to both α-particle and X-ray radi-
ation have also shown transcriptional differences between
these radiation types [23].
In the present study, genomic strategies were employed
to identify biomarkers of α-particle radiation exposure.
Circulating peripheral blood mononuclear cells (PBMCs)
were isolated from normal, healthy volunteers and exposed
to α-particle radiation. Twenty-four hours post-exposure,
the expression of transcripts was assessed using Illumina
bead array technology and these responses were com-
pared to non-irradiated controls. Dose-responsive genes
were then further assessed in independent white blood




All procedures were approved by Health Canada’s Research
Ethics Committee and a flow chart delineating the experi-
mental sequence is outlined in Figure 1. Briefly, peripheral
blood from healthy, non-smoking volunteers was drawn
via periphery venipuncture with informed consent from all
subjects into either 5 × 10 ml EDTA (for gene analysis) or
2 × 4 ml lithium heparin (for plasma analysis) vacutainer
tubes (Becton Dickinson and Company, Franklin Lakes,
NJ). A total of 6 male and 6 female donors participated.
Before any further processing, a 100 μl whole blood sample
was used for a complete blood count (CBC) via automatic
haemocytometer (Beckman Coulter, Mississauga, ON).
Peripheral blood mononuclear cell isolation
PBMCs were isolated from whole blood for an initial
global screening of gene transcripts using microarray
technology. A similar isolation procedure was employedas described by Boyum [24]. Briefly, 15 ml of Histopaque-
1077 sucrose gradient (Sigma-Aldrich, MO, USA) was
pipetted into the upper chamber of an Accuspin Tube
(Sigma-Aldrich). The tube was centrifuged (800 × g)
for 30 sec to ensure that the Histopaque was below the
frit layer. Freshly drawn whole blood was pipetted into
the upper chamber of tube. The tube was then centri-
fuged 800 × g for 15 minutes. The band of mononuclear
cells was transferred to an alternate centrifuge tube and
washed with 10 ml of isotonic phosphate buffered saline
(PBS) three times. Pelleted cells were then resuspended
in RPMI-1640 media supplemented with 10% fetal bovine
serum (FBS), 2 mM L-glutamine and 100 U penicillin &
100 μg streptomycin/ml (Sigma-Aldrich).
Total white blood cell isolation
Following initial experiments on microarray analysis of
PBMCs, further studies using qPCR were conducted on
complete WBC populations. WBCs were isolated from
whole blood using Histopaque-1119 (Sigma-Aldrich).
Twenty-five milliliters of whole blood was gently poured
over 15 ml of Histopaque-1119 and spun at 1000 × g for
10 minutes. This resulted in erythrocyte sedimentation
below the Histopaque gradient and a total white blood
cell population above the gradient. This volume (~15 ml)
was then transferred to a new 50 ml tube and diluted 1:2
with phosphate buffered saline (PBS). The resulting
WBC pellet was then washed twice more with 10 ml PBS
and resuspended in RPMI-1640 media supplemented with
10% FBS, 2 mM L-glutamine and 100U penicillin & 100 μg
streptomycin/ml.
PBMCs and WBC irradiations
Either Isolated PBMCs or WBCs were seeded at total
cell density of 8-10 × 106 cells in 2ml of media and
were cultured on thin Mylar based plastic dishes (MD)
(Chemplex Industries, Palm City, FL, USA), which
allowed for penetration of α-particles. Cells were allowed
to settle for 10 minutes before performing the irradia-
tions. Irradiations were performed at doses of 0 (control),
0.5, 1.0 or 1.5 Gy using Americium (241Am) electroplated
discs with an activity level of 66.0 kBq ± 3% (dose rate
of 0.98 ± 0.01 Gy/h, LET of 127.4 ± 0.4 keV/μm). The
absorbed dose of α-particle radiation to which the cells
were exposed was calculated using the GEANT4 v.9.1
Monte Carlo tool-kit [25]. Cells destined for X-ray radi-
ation at doses of 0 (control) 2, 5 or 10 Gy were exposed
using the X-RAD 320 X-ray irradiation system (Precision
X-ray, Inc., North Branford, CT, USA) at a higher dose
rate of 0.98 ± 0.05 Gy/min. Exposures were performed in
duplicate and pooled. Twenty-four hours following ir-
radiation, a 50 μl aliquot of cells was assessed for cellular
viability using the Trypan Blue viability assay (Bio-Rad,
Hercules, CA), and a 100 μl aliquot was used for a CBC
Figure 1 Schematic representation of the experimental process, assays and endpoints (those yielding data are shaded) for the
A) peripheral blood mononuclear cell and B) the white blood cell populations.
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cells were spun down and used for RNA extraction.
H2AX phosphorylation assay
H2AX phosphorylation was assessed using flow cyto-
metry following a modified protocol by MacPhail et al.
[26]. Thirty minutes after exposure, WBC suspensions
(5 × 105 cells per sample) were fixed with 10% formal-
dehyde (Fisher Scientific, USA) and incubated for 10 min
at room temperature. The cells were then washed and re-
suspended in 1 ml cold (−40°C), 70% methanol (Fisher
Scientific) in 1x PBS and stored at -40°C overnight or up
to two weeks. One ml of cold TBS (tris-phosphate buff-
ered saline, 0.0154 M Trizma Hydrochloride (Sigma–
Aldrich Canada), 0.5 M NaCl (Fisher Scientific), pH 7.4)
was then added to each sample, mixed well, centrifuged
(8 min, 400 × g, 4°C) and re-suspended in 1 ml of cold
TST (TBS serum triton, 96% TBS, 4% FBS (Sigma–
Aldrich), 0.1% Triton X-100 (Sigma–Aldrich)). The sam-
ples were incubated on ice for 10 min, centrifuged (5 min,
400 × g, 4°C) and re-suspended in 200 μl of anti-γ-H2AX-
fluorescein isothiocyanate (FITC) antibody (Millipore,
USA) diluted 1:500 in TST. After 2 h incubation on ice
in the dark, 1 mL of TBS with 2% FBS was added. Thesamples were then centrifuged (5 min, 400 × g, 4°C), re-
suspended in 250 μl TBS with 2% FBS. Immediately prior
to analysis by flow cytometry, 2 μl of 1 mg/mL propidium
iodide (PI) was added to each sample. For flow cytometry
analysis, data acquisition was set to analyze 2 × 104 cells
from the whole cell population as identified by a forward
scatter (FSC) vs. side scatter (SSC) dot plot. All debris
under the FSC and SSC threshold were excluded from
the analysis. The γ-H2AX response was measured by
assessing the increased level of intracellular fluorescence
characterized in the cells, as determined by the geometric
mean of the intensity peak of the anti-γ-H2AX-FITC
(channel number) of the γ-H2AX positive cells. All
samples were analyzed on a BD FACSCalibur flow cytometer
(BD Biosciences, San Jose, CA, USA).
RNA extractions
Twenty-four hours post-radiation exposure or negative
control conditions, RNA extractions were performed on
either PBMCs or WBCs. In the case of PBMCs, the cells
were resuspended in 350 μl of Buffer RLT containing 1%
β-Mercaptoethanol (Qiagen’s RNeasy Mini kit; Qiagen
Inc, Mississauga, ON) then frozen at -80°C until pro-
cessed. Frozen lysates were thawed on ice and mixed
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onto a QIAshredder spin column (Qiagen Inc), placed in
a 2 ml collection tube and centrifuged for 2 min at
~12,000 g. A volume of 350 μL of 70% ethanol was
added. Total RNA was then extracted using the RNeasy
Mini kit according to the manufacturer’s instructions
(Qiagen Inc), with the addition of Qiagen’s On-
Column RNase-free DNase (Qiagen Inc) to eliminate
any remaining DNA contamination. In the case of the
WBCs, RNA extractions were performed using QIAzol
reagent (Qiagen) and following manufacturer’s instruc-
tions. Briefly, 700 μl of QIAzol reagent was added to
the cell pellet and then homogenized via up-and-
down pipetting of the mixture 50 times. After room
temperature incubation for 15 minutes, 140 μl of chloro-
form was added for phase separation. The aqueous layer
containing RNA was then removed and precipitated with
100% ethanol. Total RNA was then isolated using the
miRNeasy column purification kit. All total RNA sample
concentrations and RNA quality were determined using
both an Agilent 2100 Bioanalyzer and RNA Nanochips
(Agilent Technologies Canada Inc., Mississauga, ON)
and spectrophotometrically (OD ratio of A260:A280)
using a Nanodrop (Fisher Scientific, Ottawa, ON). All
extracted PBMC RNA samples were determined to be
of good quality (RNA Integrity Number ≥ 8.0) with
minimal degradation and stored at -80°C until further
analysis. WBC RNA from α-particle exposed samples
was determined to be of good quality (RNA Integrity
Number ≥ 9.2) with three samples being excluded
from sample analysis due to insufficient RNA yield.
Genomic profiling
An input of 200 ng of PBMC mRNA was used for whole
genome analysis following the Illumina(r) Whole Genome
Expression Profiling Assay Guide (11317302 Rev. A).
Samples were hybridized on Illumina human-12 v2 RNA
BeadChips. BeadChips were imaged and quantified with
the Illumina iScan scanner and data was processed with
Illumina GenomeStudio v2010.2.8.11.
MiRNA profiling
An input of 200 ng of WBC miRNA expression was pro-
filed using the nCounter system (NanoString Technologies,
Seattle, WA) which profiles the expression levels of
miRNAs. This was performed using the human miRNA
expression assay (version 2) according to manufacturer’s
instructions and read using the nCounter digital analyser.
Quantitative real time-polymerase chain reaction (qPCR)
validation
Selected genes deemed statistically significant (as described
below in the Statistical analysis section) by microarray ana-
lysis or nCounter system were further assessed by qPCR.Total RNA (400 ng mRNA and 200 ng miRNA) isolated
from cells were reverse transcribed into complementary
DNA (cDNA) using the RT2 First Strand Kit (Qiagen) or
miScript Kit respectively. Gene profiling was performed ac-
cording to the manufacturer’s instructions using custom
RT2-profiler PCR arrays (Qiagen). Reactions were prepared
in 96-well plates and performed using a spectrofluoromet-
ric thermal cycler (Biorad iCycler; Hercules, CA). The rela-
tive expression of each gene was determined by using the
comparative threshold (Ct) method [27].
Customized gene array panel
A total of 84 unique identifiers were used for the deve-
lopment of a customized 384-well format gene array
panel (Table 1). This panel was comprised of genes that
were shown by microarray technology to be dose-
responsive and also expressed at 1.0 and 1.5 Gy fol-
lowing exposure of PBMC to α-particle radiation. This
panel also included a negative control gene (GNG7),
housekeeping genes (ACTB, GAPDH, GUSB, B2M) and
selected few genes derived from the work of Paul and
Amundson [16] which were not identified in this study
as statistically significant by microarray analysis (Table 1).
SABiosciences (Qiagen) designed the primers and pro-
vided a 384 well-format platform that was compatible
for use on the LightCycler 480 real-time PCR system
(Roche, Mississauga, ON). A high-throughput PCR plat-
form, comprising the Caliper Zephyr Compact Liquid
Handling Station, the Caliper Twister II plate handler
(PerkinElmer, Woodbridge, ON) and the Lightcycler 480
was employed with custom protocols developed in the
Inhalation Toxicology Laboratory of Health Canada. This
system allowed for the screening of 144 samples in a
one-week time-span.
Statistical analysis
Microarrays statistical analysis was performed as fol-
lows. Data background correction was done within
GenomeStudio (Illumina), and then exported to the lumi
R package. Data was then normalized via quantile method,
rendering the distribution of probe intensities of each
array in a set of arrays equivalent. Normalized data was
then log2 transformed for statistical comparisons. Linear
models for microarray data (LIMMA) was employed to
identify differentially expressed gene signatures between
the different exposure conditions for the PBMC micro-
array, nCounter miRNA and the WBC qPCR datasets
[28,29]. In brief, this method involves fitting a linear model
for each gene in the data and moderating the standard
error via an empirical Bayes method. This is used to esti-
mate the moderated t-statistics/F-statistics for each gene,
shrinking the standard error towards a common value.
This test is similar to an ANOVA for each gene with the
exception that standard deviations are moderated across
Table 1 Summary of transcripts on customized gene array
Alpha (All dose) Alpha (Med/High doses) X-ray Controls
Gene ID RefSeq # Gene ID RefSeq # Gene ID RefSeq # Gene ID RefSeq #
Acta2 Nm_001613 Ankra2 Nm_023039 Anxa4 Nm_001153 Gng7 Nm_000546
Aen Nm_022767 Arhgef3 Nm_019555 Ei24 Nm_004879 Gapdh Nm_004048
Apobec3h Nm_181773 Bbc3 Nm_014417 Il21r Nm_021798 Gusb Nm_002046
Ascc3 Nm_022091 Btg3 Nm_006806 Ly9 Nm_002348 B2m Nm_000181
Astn2 Nm_198187 Ccdc90b Nm_021825 Mettl7a Nm_014033 Hgdc Sa_00105
Bax Nm_004324 Cd70 Nm_001252 Myc Nm_002467 Rtc Sa_00103
Ccng1 Nm_004060 Cdkn1a Nm_000389 Plk2 Nm_006622 Ppc Sa_00104
Cmbl Nm_138809 Dcp1b Nm_152640 Plk3 Nm_004073
Ddb2 Nm_000107 Dram1 Nm_018370 Ptp4a1 Nm_003463
Fas Nm_000043 E2f7 Nm_203394 Rasgrp2 Nm_001098670
Fbxo22 Nm_012170 Eda2r Nm_021783 Slc4a11 Nm_032034
Gadd45a Nm_001924 Fam127b Nm_001078172 Tcf3 Nm_003200
GlS2 Nm_013267 Fam20b Nm_014864 Urod Nm_000374
Ier5 Nm_016545 Fdxr Nm_004110 Vwce Nm_152718
Mamdc4 Nm_206920 Fhl2 Nm_001450 Tp53 Nm_052847
Map4k4 Nm_004834 Gdf15 Nm_004864 Lig1 Nm_000234
Pcna Nm_182649 Gss Nm_000178
Phlda3 Nm_012396 Hist1h4b Nm_003544
Phpt1 Nm_014172 Igfbp4 Nm_001552
Ppm1d Nm_003620 Iscu Nm_014301
Rps27l Nm_015920 Isg20 Nm_002201
Sesn1 Nm_014454 Lamc3 Nm_006059
Tmem30a Nm_018247 Mdm2 Nm_002392
Tnfrsf10b Nm_003842 Nudt15 Nm_018283
Tnfrsf10d Nm_003840 Pcnxl2 Nm_014801
Tnfsf4 Nm_003326 Polh Nm_006502
Tp53inp1 Nm_033285 Prkab1 Nm_006253
Triap1 Nm_016399 Pvt1 Nr_003367











The array includes genes differentially expressed at all doses (0.5 - 1.5 Gy) and those only at the medium (1.0 Gy) and high (1.5 Gy) dose derived from microarray
analysis of PBMCs exposed to α-particle radiation. X-ray column represents genes that were not differentially expressed in this study but shown to be X-ray responsive,
primarily from the work of Paul and Amunduson. GNG7 is a negative control. GAPDH, GUSB, B2M are housekeeping genes. Human Genomic DNA Control (HGDC),
Reverse Transcription Control (RTC) and Positive Primer Control (PPC) are internal controls specific to the SABiosystems experimental system.
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http://www.biomedcentral.com/1755-8794/7/43genes, allowing more stable inference for each gene. Mo-
derated standard deviations are a compromise between in-
dividual genewise standard deviations and overall pooled
standard deviations. Multiple comparison false discovery
rate (FDR) was evaluated using the Benjamini-Hochberg
(BH) method [30].
PBMC qPCR data was analysed for statistical signifi-
cance without multiple correction comparison using
gene-wise ANOVA as there was a-priori reason for gene
analysis. Hierarchical clustering was performed using the
WBC qPCR data using dChip (http://www.hsph.harvard.
edu/cli/complab/dchip). This software was used to cluster
the different exposure conditions by gene signature and
group genes by similarity of expression patterns. The




To ensure that the WBC suspensions were undergoing
irradiation and sustaining DNA damage, a biological
assay indicative of DNA damage, the phosphorylation of
H2AX, was employed. Thirty minutes post-exposure, cells
were assessed for the expression of γ-H2AX, a markerFigure 2 Isolated white blood cells were used to assess H2AX phospho
A) Geometric mean of signal intensity (indicative of γ-H2AX expression) for
with n = 12 biological replicates. **represents p < 0.01 B) Representative flo
various doses of α-particle and X-ray exposure measured 30 min post-exposindicative of DNA double strand breaks. A dose-dependent
increase in the γ-H2AX signal was observed following
exposure to α-particle radiation as seen by a plot of the
geometric mean of this signal as a function of dose and the
pronounced shift in the curve (Figure 2). Statistically sig-
nificant responses were obtained at the medium (1.0 Gy)
and high (1.5 Gy) doses tested (p < 0.01) relative to the
non-irradiated control treatment group. A bi-modal
shaped curve was observed at the lowest dose of α-particle
radiation which with increasing doses transitioned to a
mono-modal curve. At the highest dose (1.5 Gy) an ap-
proximate 3-fold increase in γ-H2AX signal was observed
relative to the control sample. As a positive control, iso-
lated leukocytes were irradiated with X-rays at a high dose
rate (1 Gy/min) and a dose range of 2-10 Gy. A plot of this
response indicated X-rays to induce more double strand
breaks as seen by the marked increase in γ-H2AX signal
with dose of radiation relative to α-particle treated cells.
Genomic profiling
Genomic profiling was performed on RNA extracted
from isolated PBMCs 24 hr post-exposure. In order to
identify biomarkers, statistical stringency was prioritized
to mine for reliable genes using a Benjamini Hochbergrylation expression after exposure to α-particle or X-ray radiation.
each of the doses and radiation types. Data is presented as means ± SD










Figure 3 Venn diagram showing overlap patterns of genes
which were show to be significantly modulated via microarray
in peripheral blood mononuclear cells after various doses of
α-particle radiation. Based on an n = 12 human donors.
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tially expressed genes were filtered on flagged spots and
a BH FDR corrected p-value <0.05. A numeric summary
of the gene responses at each of the doses is provided in
Table 2. Overall, there was a pronounced induction of
transcriptional response, with the majority of genes be-
ing up-regulated in the presence of the radiation insult.
Escalating doses induced an increasing number of tran-
scripts with 30, 69 and 137 genes differentially modified
at 0.5, 1.0 and 1.5 Gy respectively. A Venn diagram was
constructed to provide a quantitative representation of
the similarities and differences in expression profiles at
each of the doses (Figure 3). Twenty-nine genes were
shown to be differentially expressed at all three doses with
expression levels ranging from 2-10 fold. Thirty-nine genes
were common between differentially expressed gene sets at
both the medium (1.0 Gy) and high (1.5 Gy) dose. The
range in expression levels of these 68 genes is summarized
as a heat map which delineates the genes by degree of fold
change (Figure 4).
QPCR validation
All 68 genes observed to be differentially expressed were
further validated using qPCR. A comparison of the
responses using the two technologies showed a similar
trend in differential expression levels. As shown in Table 3,
all genes that exhibited a significant response across the 3
doses using microarray analysis were also observed to
exhibit a similar trend using qPCR. However, approximately
20% of the total validated targets were shown to be non-
significant using qPCR. This is not unexpected as in
comparison to microarrays, qPCR may report different sta-
tistical assignments [31]. In contrast, there were also a sub-
set of 9 genes which showed statistical significance at the
0.5 Gy dose via qPCR but not using microarray analysis.Table 2 Numeric summary of differentially expressed
transcripts that were obtained from exposure of isolated
PBMC to α-particle radiation and categorized by dose
0.5 Gy 1.0 Gy 1.5 Gy
Number of transcripts 30 69 137
Common amongst doses (%) 29 (97) 29 (42) 29 (21)
Exclusive (%) 1 (3) 1 (1) 69 (50)
Up regulated (%) 29 (97) 68 (99) 120 (88)
Common amongst doses (%) 29 (100) 29 (42) 29 (23)
Exclusive (%) 0 (0) 1 (100) 53 (39)
Down regulated (%) 1 (3) 1 (1) 17 (12)
Common amongst all doses (%) 0 (0) 0 (0) 0 (0)
Exclusive (%) 1 (100) 0 (0) 16 (12)
Bracketed numbers indicate the percentage of transcripts that were expressed
in each of the categories from the total number of genes responding at
each dose.Custom qPCR panel
A customized gene array panel was developed to more
cost-effectively assess whether the differentially respond-
ing genes observed from the microarray dataset were
expressed in the WBC population, remained differen-
tially expressed following exposure to α-particle radi-
ation and were responsive to X-ray exposures.
WBCs were isolated from 12 healthy individuals and
exposed to α-particles and X-rays. Total white blood cell
counts were typically in the range of 5-10 × 106 cells/mL.
The viability of the cells was assessed using the Trypan
Blue viability assay pre- and post-irradiation. The cells
remained viable (above 98%) and no significant changes in
blood cell counts or populations subsets were observed
post-irradiation relative to unirradiated cells (Table 4).
Twenty-four hours after irradiation, RNA was extracted
and reverse transcribed to cDNA. A comparison of the dif-
ferential gene responses obtained from the qPCR of WBCs
and microarray analysis of PBMCs showed similar fold
change and statistical significance for the majority of the
68 transcripts that were assessed (Table 5). These respon-
ding genes were compared to those obtained for X-ray
exposed cells. Box-plots of the responding genes from the
WBC qPCR dataset allowed for a visual comparison of the
two radiation types and the range in inter-individual vari-
ability between transcripts (Figure 5). Overall, all genes
responsive in α-particle treated cells were also observed to
be expressed in X-irradiated cells. The data displayed mi-
nimal variability between control treatment groups under
varied radiation exposure conditions. Furthermore, the ma-
jority of genes displayed dose-response trends for both
A) B)
Figure 4 Heat map depicting PBMC fold change microarray gene expression values from those shown to be statistically significant at
all A) three doses (0.5, 1.0, 1.5 Gy) and B) the medium (1.0 Gy) and high (1.5 Gy) dose. Red colouring signifies up-regulation and green
colouring signifies down-regulation based on an n = 12 biological replicates.
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(Figure 6) was further used to display groupings and
make class distinctions. The two control groups clustered
together as expected and showed a distinct trend relative
to the other exposed groups. The lowest dose of radiation
(0.5 Gy α-particle) also clustered with the unexposed
groups. The next largest classification comprised the
remaining exposure groups, in which the 2 Gy X-ray, 1.0
and 1.5 Gy α-particle and 5 and 10 Gy X-ray were classi-
fied further from the controls in order of descending
similarity respectively. The subsequent clustering of the
1.0 and 1.5 Gy α-particle exposure and the 5 and 10 Gy
X-ray exposure together suggests that it is possible to
make distinctions between high X-ray radiation doses
and α-particle doses using a clustering algorithm.
MicroRNA expression
The screening of ~800 miRNA transcripts using Nano-
String profiling resulted in a minimal number of respondingtargets. Only one miRNA (miR-34a) was observed to be
differentially modulated (p < 0.05) across all doses fol-
lowing α-particle radiation exposure in WBC. This
target was dose-responsive and subsequently validated
using qPCR (Table 6). miR-34a was up-regulated over 2.5
fold in all exposed samples and had a similar 3 fold
induction in the 1.0 and 1.5 Gy α-particle doses. This tar-
get was not specific to α-particle exposure as expression
was also observed with X-ray irradiation at all three doses
tested.
Discussion
The overarching goal of this research was to identify
genes responsive to α-particle radiation exposure for the
purposes of developing effective triage tools for use in a
population radiation exposure scenario. To date, the
majority of genomic-based biomarker radiation studies
have focused on photon radiation. Although there is a
large body of work concerning radiation exposure and
Table 3 Validation of PBMC gene responses identified by microarray via qPCR
Radiation type 0.5 Gy alpha 1.0 Gy alpha 1.5 Gy alpha
Technology qPCR MA qPCR MA qPCR MA
Symbol FC PV FC PV FC PV FC PV FC PV FC PV
All doses
TRIAP1 2.15 0.00 1.81 0.00 3.32 0.00 2.14 0.00 3.78 0.00 2.57 0.00
GADD45A 2.94 0.00 2.27 0.01 4.43 0.00 2.77 0.00 4.70 0.00 3.38 0.00
RPS27L 2.01 0.00 1.67 0.01 2.59 0.00 1.90 0.00 3.57 0.00 2.04 0.00
MAP4K4 1.51 0.01 1.40 0.05 1.79 0.00 1.54 0.00 1.90 0.00 1.69 0.00
TNFRSF10D 2.15 0.01 1.81 0.01 2.94 0.00 2.08 0.00 3.08 0.00 2.39 0.00
ASTN2 6.18 0.01 2.07 0.01 8.02 0.00 2.67 0.00 8.98 0.00 3.15 0.00
TNFRSF10B 2.28 0.01 2.02 0.01 3.06 0.00 2.32 0.00 3.13 0.00 2.72 0.00
TMEM30A 1.92 0.01 1.72 0.01 2.67 0.00 2.13 0.00 2.76 0.00 2.45 0.00
TP53INP1 1.56 0.01 1.53 0.04 1.83 0.00 1.81 0.00 1.88 0.00 2.02 0.00
BAX 2.42 0.01 2.31 0.00 3.17 0.00 2.88 0.00 3.89 0.00 3.23 0.00
FAS 1.89 0.01 1.79 0.00 2.61 0.00 2.06 0.00 2.94 0.00 2.23 0.00
DDB2 2.96 0.01 3.56 0.00 5.15 0.00 4.41 0.00 5.26 0.00 5.49 0.00
AEN 4.24 0.01 2.16 0.01 7.09 0.00 2.80 0.00 7.46 0.00 3.14 0.00
GLS2 1.94 0.01 1.87 0.01 2.30 0.00 2.37 0.00 2.46 0.00 2.62 0.00
CMBL 3.99 0.01 2.52 0.01 6.79 0.00 2.90 0.00 7.41 0.00 3.57 0.00
PHPT1 2.28 0.02 2.23 0.00 3.50 0.00 2.57 0.00 4.17 0.00 3.03 0.00
PCNA 2.49 0.02 2.02 0.00 3.64 0.00 2.44 0.00 4.09 0.00 2.88 0.00
ASCC3 2.14 0.03 1.84 0.00 3.18 0.00 2.22 0.00 3.28 0.00 2.37 0.00
PPM1D 1.58 0.05 1.63 0.01 2.14 0.00 1.81 0.00 2.17 0.00 2.11 0.00
XPC 1.62 0.05 1.81 0.01 2.20 0.00 2.12 0.00 2.00 0.01 2.31 0.00
IER5 2.09 0.05 1.82 0.01 2.71 0.00 2.10 0.00 3.09 0.00 2.41 0.00
TNFSF4 2.91 0.06 2.93 0.00 4.98 0.00 3.69 0.00 5.34 0.00 4.67 0.00
SESN1 1.40 0.06 1.90 0.00 2.25 0.00 2.14 0.00 1.98 0.01 2.44 0.00
FBXO22 1.40 0.08 1.39 0.03 1.97 0.01 1.56 0.00 2.17 0.00 1.65 0.00
PHLDA3 9.91 0.09 3.18 0.00 22.89 0.00 3.96 0.00 28.82 0.00 4.89 0.00
ACTA2 2.12 0.09 2.54 0.01 2.72 0.01 3.07 0.00 2.74 0.01 3.60 0.00
CCNG1 0.91 0.10 1.80 0.00 2.49 0.00 1.97 0.00 2.56 0.00 2.14 0.00
MAMDC4 2.54 0.14 2.06 0.04 3.18 0.02 2.82 0.00 3.52 0.01 3.23 0.00
APOBEC3H 2.38 0.55 2.52 0.04 3.68 0.08 3.20 0.00 4.49 0.02 3.91 0.00
Med/High doses
SAC3D1 1.47 0.01 1.26 0.24 1.74 0.00 1.29 0.04 1.91 0.01 1.33 0.01
PVT1 2.02 0.01 1.42 1.00 2.76 0.00 1.68 0.02 3.45 0.00 1.85 0.00
TP53TAP1 1.42 0.01 1.20 1.00 1.60 0.00 1.39 0.03 1.92 0.01 1.45 0.01
TNFSF8 2.40 0.01 1.92 0.08 4.01 0.00 2.33 0.00 3.80 0.00 2.61 0.00
TMPRSS7 4.04 0.01 1.24 1.00 4.85 0.01 1.53 0.00 6.74 0.00 1.52 0.00
ZNF79 1.74 0.02 1.39 0.47 2.07 0.00 1.74 0.00 2.34 0.00 1.95 0.00
SLC7A6 1.64 0.03 1.62 0.15 1.98 0.01 1.89 0.00 2.22 0.00 2.15 0.00
CDKN1A 2.41 0.03 2.30 0.11 3.87 0.00 2.94 0.00 5.05 0.00 3.58 0.00
MDM2 2.93 0.04 1.24 0.31 4.44 0.00 1.30 0.02 5.17 0.00 1.45 0.00
FDXR 6.46 0.06 1.47 0.85 13.07 0.00 1.76 0.01 14.43 0.00 1.88 0.00
DCP1B 1.68 0.06 1.17 1.00 2.00 0.00 1.45 0.01 2.33 0.00 1.51 0.00
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Table 3 Validation of PBMC gene responses identified by microarray via qPCR (Continued)
BBC3 4.10 0.06 1.40 0.66 6.75 0.00 1.65 0.01 7.25 0.00 1.83 0.00
ISG20 0.75 0.06 -1.44 1.00 0.46 0.00 -1.92 0.00 0.46 0.00 -2.30 0.00
FAM20B 1.49 0.07 1.08 1.00 1.45 0.01 1.25 0.03 1.55 0.01 1.35 0.00
DRAM1 1.41 0.07 1.32 1.00 1.70 0.00 1.55 0.03 1.91 0.00 1.66 0.00
CCDC90B 2.18 0.07 1.20 0.64 1.54 0.07 1.29 0.02 2.89 0.00 1.35 0.00
POLH 1.72 0.08 1.39 0.24 2.37 0.00 1.60 0.00 2.10 0.01 1.92 0.00
GSS 1.19 0.08 1.15 1.00 1.34 0.01 1.29 0.03 1.60 0.00 1.34 0.00
PRKAB1 1.40 0.08 1.29 0.59 1.62 0.01 1.49 0.00 1.85 0.00 1.60 0.00
ARHGEF3 1.37 0.09 1.32 0.59 1.74 0.01 1.51 0.00 1.68 0.02 1.55 0.00
ZNF337 1.23 0.11 1.34 0.25 1.53 0.02 1.44 0.01 1.61 0.02 1.52 0.00
HIST1H4B 1.34 0.11 1.83 0.75 1.62 0.02 2.21 0.03 1.79 0.01 2.59 0.00
LAMC3 2.76 0.12 1.54 1.00 3.63 0.00 1.93 0.02 4.50 0.00 2.13 0.00
GDF15 1.84 0.14 1.49 1.00 2.40 0.01 1.98 0.03 2.96 0.05 2.26 0.00
ISCU 1.15 0.15 1.18 0.98 1.29 0.01 1.24 0.05 1.47 0.00 1.26 0.01
TRIM22 1.28 0.15 1.69 0.25 1.96 0.02 2.06 0.00 1.63 0.02 2.16 0.00
BTG3 1.11 0.23 1.30 0.21 1.69 0.00 1.41 0.00 1.70 0.01 1.54 0.00
NUDT15 1.22 0.23 1.21 0.24 1.48 0.02 1.31 0.00 1.47 0.03 1.38 0.00
RETSAT 1.25 0.27 1.21 1.00 1.16 0.56 1.38 0.03 1.19 0.29 1.45 0.00
TRIM32 1.32 0.27 1.25 0.45 1.10 0.15 1.34 0.02 1.58 0.04 1.37 0.00
FHL2 1.74 0.30 1.50 0.44 2.47 0.02 1.82 0.00 2.65 0.01 2.20 0.00
FAM127B 1.14 0.30 1.21 0.54 1.53 0.01 1.31 0.00 1.58 0.05 1.38 0.00
PCNXL2 1.23 0.37 1.19 1.00 1.18 0.52 1.33 0.01 1.34 0.15 1.40 0.00
E2F7 2.23 0.37 1.33 1.00 3.19 0.39 1.49 0.05 4.08 0.43 1.72 0.00
TOB1 1.02 0.40 1.23 0.69 1.40 0.02 1.38 0.00 1.40 0.03 1.47 0.00
ANKRA2 1.07 0.44 1.39 0.27 1.63 0.01 1.48 0.02 1.60 0.02 1.60 0.00
CD70 2.45 0.55 2.04 0.75 4.44 0.04 2.50 0.04 5.05 0.03 3.01 0.00
EDA2R 8.96 0.61 1.31 1.00 19.58 0.87 1.57 0.02 31.64 0.29 1.67 0.00
IGFBP4 1.19 0.68 1.19 1.00 1.61 0.06 1.45 0.01 1.63 0.05 1.52 0.00
A comparison of the gene expression fold change (FC) responses obtained using microarray technology (MA) and qPCR at the three doses (0.5-1.5 Gy) of α-particle
radiation examined. Transcripts that were shown to be differentially expressed at all three doses and the medium (1.0 Gy) and high (1.5 Gy) dose were validated
using qPCR. PV indicates the p-value obtained using either ANOVA or microarray statistics. The table is divided into two sections; the first section is comprised of
genes that were shown to be significant using MA technology at all three doses and the second section are those genes that were shown to be significant using
MA technology at the medium (1.0 Gy) and high (1.5 Gy) dose.
Table 4 A typical representation of complete blood counts from isolated white blood cells obtained from healthy
individuals post-exposure
Exposure Viability WBC total Neutrophils Lymphocytes Monocytes Eosinophil Basophils
Condition (Gy) (%) (Cell/ml × 106)
Alpha 0.0 98.0 4.0 1.78 (45%) 1.86 (47.1%) 0.26 (6.7%) 0.04 (1.1%) 0.00 (0.1%)
Alpha 0.5 99.0 3.8 1.69 (44.4%) 1.86 (48.9%) 0.22 (5.9%) 0.02 (0.6%) 0.01 (0.2%)
Alpha 1.0 99.0 3.8 1.73 (45.1% 1.86 (48.4%) 0.2 (5.3%) 0.04 (1.0%) 0.01 (0.2%)
Alpha 1.5 99.0 3.7 1.69 (48%) 1.76 (48%) 0.19 (5.1%) 0.03 (0.8%) 0.00 (0.00%)
X-Ray 0.0 99.0 3.8 1.76 (45.8%) 1.88 (48.9%) 0.17 (4.4%) 0.03 (0.8%) 0.00 (0.1%)
X-Ray 2.0 99.0 3.8 1.74 (46.3%) 1.82 (48.4%) 0.16 (4.2%) 0.03 (0.9%) 0.01 (0.2%)
X-Ray 5.0 99.0 3.7 1.70 (46%) 1.80 (48.9%) 0.13 (3.6%) 0.05 (1.4%) 0.00 (0.1%)
X-Ray 10.0 99.0 4.0 1.85 (45.7%) 2.03 (50.4%) 0.11 (2.8%) 0.04 (1.0%) 0.00 (0.1%)
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Table 5 WBC transcriptional profiling post α-particle and X-ray radiation via custom qPCR array
Radiation type Alpha X-ray
Dose (Gy) 0.5 1.0 1.5 2.0 5.0 10.0
Gene ID FC PV FC PV FC PV FC PV FC PV FC PV
All doses
DDB2 4.65 0.00 8.45 0.00 8.76 0.00 5.37 0.00 8.59 0.00 9.12 0.00
PCNA 3.30 0.00 6.05 0.00 7.27 0.00 3.80 0.00 5.76 0.00 7.47 0.00
AEN 6.02 0.01 12.22 0.00 13.86 0.00 12.67 0.00 15.88 0.00 18.58 0.00
TNFSF4 4.71 0.03 9.04 0.00 11.01 0.00 5.56 0.00 10.64 0.00 14.46 0.00
PHPT1 2.65 0.03 4.22 0.00 4.96 0.00 3.68 0.00 4.73 0.00 5.70 0.00
TNFRSF10B 2.29 0.03 3.94 0.00 3.52 0.00 3.66 0.00 5.27 0.00 5.47 0.00
MAP4K4 1.90 0.05 2.29 0.00 2.49 0.00 2.03 0.00 2.28 0.00 2.50 0.00
GLS2 2.00 0.06 2.45 0.00 2.62 0.00 2.66 0.00 3.73 0.00 4.37 0.00
ACTA2 1.99 0.07 2.48 0.00 2.90 0.00 1.95 0.01 2.35 0.00 2.82 0.00
TRIAP1 2.88 0.07 4.27 0.00 5.18 0.00 2.87 0.00 4.11 0.00 5.03 0.00
IER5 2.02 0.09 2.82 0.00 2.79 0.00 2.75 0.00 3.85 0.00 4.47 0.00
APOBEC3H 7.03 0.10 13.35 0.00 16.63 0.00 7.82 0.00 12.59 0.00 17.99 0.00
TNFRSF10D 2.64 0.10 3.83 0.00 4.91 0.00 3.49 0.00 3.81 0.00 4.66 0.00
XPC 2.43 0.13 4.00 0.00 2.99 0.00 3.76 0.00 3.89 0.00 4.28 0.00
PPM1D 2.21 0.13 2.65 0.02 3.18 0.00 2.17 0.00 2.81 0.00 3.55 0.00
BAX 3.35 0.15 5.35 0.00 6.56 0.00 5.21 0.00 5.83 0.00 7.19 0.00
PHLDA3 19.38 0.23 50.31 0.00 46.15 0.00 26.63 0.00 37.99 0.00 47.11 0.00
ASTN2 5.85 0.24 10.73 0.01 10.09 0.01 10.41 0.00 15.76 0.00 16.68 0.00
GADD45A 4.76 0.30 8.33 0.01 8.07 0.00 7.35 0.00 10.87 0.00 14.02 0.00
MAMDC4 3.32 0.36 4.77 0.03 4.98 0.01 3.86 0.00 5.09 0.00 5.68 0.00
CMBL 7.34 0.43 16.13 0.01 19.65 0.00 10.40 0.00 13.33 0.00 18.53 0.00
SESN1 1.83 0.55 2.86 0.04 3.45 0.00 2.41 0.02 2.72 0.04 2.54 0.02
ASCC3 2.82 0.53 4.35 0.08 5.48 0.01 4.06 0.00 4.63 0.02 5.45 0.00
CCNG1 2.12 0.55 3.35 0.05 4.22 0.00 2.88 0.02 3.23 0.03 3.80 0.00
FBXO22 1.70 0.66 2.41 0.16 3.10 0.02 2.39 0.01 2.63 0.06 2.93 0.01
TP53INP1 1.46 0.66 1.80 0.28 2.20 0.04 1.73 0.05 1.74 0.33 2.10 0.06
FAS 1.72 0.72 2.28 0.30 3.19 0.02 1.80 0.07 2.07 0.46 2.41 0.20
RPS27L 2.34 0.99 3.76 0.89 5.96 0.61 3.83 0.05 3.23 0.90 4.57 0.67
TMEM30A 1.91 0.99 2.82 0.87 4.04 0.56 2.82 0.06 2.70 0.90 3.42 0.67
Med/High dose
BBC3 5.15 0.03 9.60 0.00 10.83 0.00 6.80 0.00 9.67 0.00 11.92 0.00
TNFSF8 2.98 0.03 5.64 0.00 6.38 0.00 4.57 0.00 5.65 0.00 7.34 0.00
PVT1 3.20 0.04 5.09 0.00 5.76 0.00 3.76 0.00 5.58 0.00 6.89 0.00
FDXR 10.88 0.05 24.04 0.00 27.24 0.00 17.01 0.00 27.84 0.00 37.91 0.00
TRIM32 1.80 0.05 1.96 0.01 2.01 0.01 1.71 0.01 2.11 0.00 2.48 0.00
ANKRA2 1.54 0.05 2.07 0.00 2.15 0.00 1.73 0.00 2.01 0.00 2.12 0.00
GSS 1.44 0.05 1.67 0.00 1.69 0.00 1.44 0.01 1.72 0.00 2.01 0.00
HIST1H4B 1.79 0.07 2.06 0.00 1.96 0.01 1.67 0.04 2.09 0.00 2.59 0.00
ARHGEF3 1.62 0.07 2.03 0.00 2.20 0.00 1.98 0.00 2.47 0.00 2.83 0.00
SLC7A6 2.37 0.09 3.19 0.00 3.94 0.00 2.42 0.00 3.25 0.00 4.28 0.00
CD70 5.76 0.13 10.08 0.00 12.92 0.00 6.14 0.00 9.06 0.00 9.89 0.00
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Table 5 WBC transcriptional profiling post α-particle and X-ray radiation via custom qPCR array (Continued)
ZNF79 1.96 0.13 2.58 0.00 3.17 0.00 2.18 0.00 2.95 0.00 3.68 0.00
TOB1 1.39 0.13 1.61 0.00 1.74 0.00 1.26 0.13 1.63 0.00 1.78 0.00
ZNF337 1.42 0.37 1.88 0.00 2.08 0.00 1.66 0.01 1.92 0.00 2.30 0.00
PRKAB1 1.67 0.38 2.06 0.05 2.32 0.02 1.81 0.01 2.06 0.01 2.38 0.00
BTG3 1.58 0.38 1.87 0.04 2.15 0.01 1.66 0.02 1.94 0.01 2.06 0.00
POLH 1.74 0.42 2.34 0.07 2.16 0.13 2.01 0.02 2.44 0.02 2.92 0.00
MDM2 3.83 0.43 6.10 0.05 8.91 0.00 3.76 0.01 5.24 0.01 8.33 0.00
DCP1B 1.84 0.46 2.59 0.04 2.37 0.07 2.47 0.00 2.98 0.00 3.39 0.00
FAM20B 1.41 0.53 1.54 0.23 1.60 0.17 1.50 0.02 1.73 0.01 1.91 0.00
PCNXL2 1.26 0.55 1.44 0.09 1.45 0.11 1.23 0.21 1.51 0.02 1.76 0.00
ISG20 -1.18 0.58 -1.53 0.11 -1.36 0.28 -1.55 0.49 -1.67 0.11 -1.61 0.18
CDKN1A 3.12 0.62 4.70 0.20 6.97 0.02 3.67 0.01 4.52 0.13 6.84 0.00
LAMC3 3.76 0.66 4.94 0.47 6.68 0.21 4.42 0.02 4.42 0.33 5.89 0.12
DRAM1 1.54 0.66 2.00 0.19 2.62 0.02 1.56 0.12 1.92 0.25 2.17 0.08
RETSAT 1.27 0.66 1.42 0.28 1.19 0.35 1.82 0.02 2.09 0.01 2.35 0.00
ISCU 1.25 0.66 1.43 0.22 1.86 0.01 1.45 0.03 1.53 0.11 1.62 0.02
EDA2R 13.97 0.73 30.23 0.36 39.14 0.15 11.63 0.02 14.28 0.27 13.00 0.20
NUDT15 1.48 0.74 1.85 0.23 2.66 0.03 1.73 0.03 1.84 0.25 1.91 0.14
FHL2 1.66 0.74 2.77 0.16 2.56 0.20 1.69 0.05 2.23 0.13 2.84 0.01
CCDC90B 1.42 0.88 1.68 0.53 2.28 0.04 1.56 0.22 1.57 0.83 1.82 0.42
IGFBP4 1.51 0.92 2.54 0.55 2.81 0.40 2.45 0.02 2.77 0.37 3.23 0.15
SAC3D1 1.46 0.94 1.69 0.77 2.01 0.56 2.04 0.04 2.12 0.51 2.85 0.17
E2F7 -1.98 0.94 -1.26 0.87 1.26 0.92 -1.00 0.31 1.56 0.51 2.61 0.50
FAM127B 1.57 0.98 1.56 0.90 2.18 0.52 1.94 0.06 1.74 0.90 1.96 0.76
TMPRSS7 1.66 0.99 1.55 0.73 2.56 0.76 4.16 0.13 5.92 0.34 8.32 0.05
GDF15 2.98 0.99 5.21 0.87 4.54 0.78 2.90 0.05 2.37 0.94 4.61 0.62
TRIM22 1.67 0.99 2.27 0.89 3.15 0.56 2.20 0.06 1.91 0.96 1.89 0.85
TP53AP1 1.37 0.99 1.62 0.90 2.32 0.49 1.73 0.07 1.53 0.97 1.95 0.77
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radiation may elicit differential cellular response due to
its characteristic physical properties, which differ from
photon radiation. This may potentially provide more ac-
curate dose estimates for exposures and allow for differ-
entiation between radiation types.
Circulating blood cells represent a sensitive target for
early radiation damage and are easily accessible. Isolated
leukocytes from healthy individuals were ex-vivo irradi-
ated at a dose range of 0-1.5 Gy at 0.98 Gy/h. These
doses were selected based on their relevance to an actual
radiological dispersal device scenario [32], where the dose
deposition is approximately 0.5 Gy per α-particle track
[33]. Furthermore, previous studies from our laboratory
have shown observable biological damage at this dose-
range and a time-point of 24 hours post-exposure [34-36].
The X-ray exposure doses and dose rates were selected
based on the work by Paul and Amundson [16]. Althoughwhole blood was employed by Paul and Amundson, the
limitations of our exposure system only allowed for the
use of isolated leukocytes. It was observed that the red
blood cells in whole blood minimized the transversal of
α-particles through other cell types as measured by DNA
double strand breaks via γ-H2AX (data not shown). Leu-
kocytes exposed to α-particles displayed lower γ-H2AX
intensities than the X-ray exposed samples possibly due
to several factors. Firstly, the samples irradiated with
X-rays were exposed to higher overall doses which in-
crease the probability of inducing DNA double strand
breaks. Secondly, the dose rates of exposure were mark-
edly different. The α-particle exposure system is limited
to a dose rate of ~1 Gy/hr and the X-ray exposure was
performed at a dose rate of ~1 Gy/minute. This means the
α-particle doses were delivered over a protracted amount
of time relative to the X-rays. It has been previously docu-
mented that γ-H2AX foci reach a peak 30 minutes after
Figure 5 Box-plot representation of the 84 gen custom array panel derived from the qPCR data of isolated white blood cells exposed
to α-particle and X-ray radiation. Genes are listed alphabetically and are plotted with 2-ΔCTvalues along the Y-axis. The central line represents
the median of the data and the box edges represent the upper (75th) and lower (25th) percentile. Whiskers denote the highest and lowest values
from the data set within the upper and lower limits. Limits are defined as 1.5*50 percentile spread.
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The time-scale of the higher doses (1.0, 1.5 Gy) of α-
particle radiation exposure is between ~1-1.5 hours.
Thus, there is a degree of repair occurring as the cells
undergo irradiation and the measured signal is lowered
due to resolved H2AX foci. There is an eventual equilib-
rium between induction and repair; it would be expected
that the signal intensity would be higher for an acute ex-
posure of an equivalent dose. All of the X-ray exposures
were conducted on the order of minutes, with the highest
(10 Gy) dose approximating 10 minutes.
A preliminary microarray screening following the
exposure of isolated PBMC to α-particles identified 29
genes responsive at all doses tested (0.5-1.5 Gy) and 39
which responded only to the medium (1.0 Gy) and high
(1.5 Gy) dose. These genes were validated using qPCR
and shown through pathway analysis to be associated with
signaling pathways centered around p53 and GADD45A,
consistent with a DNA damage response (data not shown).
To confirm the validity of this gene set in a more physiolo-
gically relevant population of cells, the complete white
blood cell population was harvested. Furthermore, theability of this gene panel to discriminate between radiation
qualities was concurrently assessed using X-ray exposures.
For this purpose, a customized gene panel was constructed
using genes identified as significantly modulated by micro-
array analysis and included a selected few identified in the
literature as being X-ray-responsive, primarily from the
work conducted by Paul and Amundson [16].
The customized gene panel confirmed the validity of
our initial microarray results. Primarily, genes differen-
tially responsive in PBMC were also observed to be sig-
nificantly expressed in the total WBC population using
qPCR. However, a selected few genes were shown to lack
statistical significance at 0.5 Gy, most likely due to the
use of stringent statistical analysis accounting for mul-
tiple statistical comparisons and FDR correction using
Benjamini-Hochberg testing [28]. When no FDR correc-
tion was employed, the qPCR dataset were more com-
parable to the PBMC microarray results. This is not
unexpected as in comparison to microarrays, qPCR may
report different statistical assignments [31,38].
Further visualization of the data using box plots allowed
for an assessment of the gene responses with respect to
Figure 6 Median based hierarchical clustering dataset to
determine common groupings of samples and genes. Dataset is
obtained from qPCR results in isolated white blood cells exposed to
α-particle and X-ray radiation.
Chauhan et al. BMC Medical Genomics 2014, 7:43 Page 14 of 16
http://www.biomedcentral.com/1755-8794/7/43individual variability. All control treatment groups
displayed low inter-individual variability for the majo-
rity of differentially expressed transcripts, particularly
between radiation types, highlighting the potential for
these transcripts to be strong biomarkers. Furthermore,
the majority of genes displayed dose-response trends
for both α-particle and X-ray radiation. This is further
highlighted in the hierarchical clustering of the dataset.
Inputting all qPCR data resulted in the classification ofTable 6 qPCR validation of miRNA profiling results
Radiation type Alpha
Dose (Gy) 0.5 1.0 1.5
miRNA FC PV FC PV FC
miR-34a 2.67 0.00 3.05 0.00 3.14
Total isolated RNA from irradiated leukocytes was profiled with the nCounter system
donors. FC = fold change, PV = p-value.treatment groups based on exposure doses. Clustering of
the 1.0 and 1.5 Gy α-particle exposures together and the
5 and 10 Gy X-ray exposure suggests potential for
distinctions to be made between high X-ray radiation
doses and comparably lower α-particle doses.
Overall, the gene-expression changes induced by α-
particle radiation were not distinct from the X-ray
responses. Although all genes modulated in the α-particle
exposed WBCs were also observed after X-ray expo-
sure, there were differing degrees of induction. In a
selected few genes, α-particle doses of 1.0 Gy at a dose
rate of ~1 Gy/hr were able to elicit the same fold induc-
tion as a 10 Gy X-ray dose at ~ 1 Gy/min. Thus, despite
there being an order of magnitude difference in dose and
a greater than fifty fold difference in dose rate between
the radiation exposures, a similar cellular response was
observed. It has been previously established that the
lesions caused by α-particle tracks display different repair
kinetics and fidelity [39]. Only a 24 hour time point was
examined in this study and there may be pronounced
temporal differences in gene expression resulting from
the differing degrees of damage and repair between the
radiation types.
To date, Turtoi et al., [40] is the only other group
to examine α-particle radiation induced genomic-wide
transcriptional effects in isolated blood cells. This group
employed a harvest time of 1hr post-irradiation using a
dose range of 0.05 - 1.6 Gy of α-particle radiation. Three
hundred and thirty nine genes were shown to be diffe-
rentially modified with 54% up-regulated and 46%
down-regulated. In comparison, the present study identi-
fied fewer genes, the majority of which were upregulated.
These differences may be attributed to experimental
conditions, as Turtoi et al., used varying dose-rates and a
post-irradiation harvest time of 1 hour. As well, their gene
responses were obtained from only one individual, whereas
the present study used 12 different donors.
Conclusion
In summary, genomic strategies were employed for the
identification of gene-based responses in PBMCS and
WBCs exposed to α-particle radiation. Genomic screen-
ing of PBMCs exposed to α-particle radiation identified
twenty-nine transcripts that responded at 0.5, 1.0 and 1.5
Gy and thirty-nine genes were shown to be differentiallyX-ray
2.0 5.0 10.0
PV FC PV FC PV FC PV
0.00 3.14 0.00 3.30 0.00 3.05 0.00
and subsequently validated via qPCR. Results are presented from n = 12
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comparison using WBCs with high dose-rate X-ray ra-
diation showed that both radiation types elicited similar
gene responses with varying degree of fold induction.
No α-particle exclusive gene modulations were identified.
Therefore, current gene panels for photon radiation may
also be applicable for use in α-particle radiation bio-
dosimetry. Future work includes testing the gene panel in
an in vivo environment, using radiotherapy patients
undergoing either total body irradiations or α-particle
radiation therapy.
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